Cancer Research

#AACR #AACR 2025 #Cancer #Cancer research #Cancer therapeutics #Oncology

Insight from AACR 2025

The American Association of Cancer Research (AACR) Annual Meeting took place from 25-30 April at the McCormick Place Convention Center in Chicago, US. DDW’s Megan Thomas looks at key announcements, presentations and breakthroughs that took place. Presidential commentary On Sunday 27 April, attendees were welcomed at the Opening Ceremony by… Read More

#Cancer Research #Exclusive Content

#Akiram Therapeutics #Clinical trials #Radiotherapy #Sweden

First patient enrolled in Phase I trial of Akiram’s cancer drug

Akiram Therapeutics, a Swedish biotech company specialising in targeted radiotherapy, has enrolled the first patient in the Phase I clinical trial of its drug candidate 177Lu-AKIR001. The trial is being conducted at Karolinska University Hospital, which also acts as the study sponsor, and marks an important milestone in Akiram’s efforts… Read More

#Cancer Research #News

#AACR #Clasp Therapeutics #Oncology #Phase I trial #T cell engagers

First precision T-cell engager for solid tumours enters the clinic

Clasp Therapeutics has announced the dosing of the initial patient in the GUARDIAN-101 Phase I trial of CLSP-1025, the first tumour-specific TCE to enter clinical development.   The company also presented non-clinical data for CLSP-1025 at the 2025 American Association for Cancer Research (AACR) Annual Meeting. … Read More

#Cancer Research #Editor's Choice #News

#AACR #Cancer research #Funding #Oncology

New $15 million cancer research grant launched at AACR

The AACR Trailblazer Cancer Research Grant Program, which was launched at the Annual Meeting Opening Ceremony, will award $15 million over three years.  It is designed for early-stage and mid-career investigators to support meritorious and promising cancer research.  “AACR has been a proud funder of… Read More

#Cancer Research #News

Immunotherapy
#Cancer research #Candel Therapeutics #Immunotherapy #Solid tumours

Gene delivery evolution: Advancing novel cancer immunotherapies

DDW Editor Megan Thomas speaks to Paul Peter Tak, President and CEO of Candel Therapeutics, about the company’s cancer data and its development of next-generation viral immunotherapies targeting solid tumours. MT: Please provide a brief overview of Candel’s pipeline? PT: Candel’s clinical stage pipeline is built on two distinct multimodal… Read More

#Cancer Research #Exclusive Content

CAR-T cell attacking cancer
#Cancer therapy #CAR-T #Cell therapy #Cytokine Release Syndrome (CRS) #Cytokines #Poolbeg Pharma

CRS prevention: Taking the sting from CAR-T’s tail

Advances in cancer therapy have produced powerful treatments that can greatly improve survival – but can also trigger fearsome side-effects. Notably, CAR-T cell therapies can cause cytokine release syndrome (CRS). Managing CRS is an area that is becoming increasingly important to Big Pharma, reports DDW’s Megan Thomas. CAR-T cell cancer… Read More

#Cancer Research #Exclusive Content

Cancer cell
#Astex Pharmaceuticals #Combination therapy #Mosaic Therapeutics #Oncology

Mosaic in-licenses clinical-stage oncology assets from Astex

Mosaic Therapeutics has in-licensed two clinical-stage oncology programmes from Astex Pharmaceuticals, a subsidiary of Otsuka Pharmaceutical.  Mosaic has identified combinations incorporating the licensed products and their targets and the agreement gives Mosaic the exclusive rights to develop those combination products for patients for whom there are no,… Read More

#Business & Investment #Cancer Research #News

#Artificial intelligence (AI) #AstraZeneca #Foundational model #Oncology

Partners to build largest multimodal oncology foundation model

AstraZeneca, Tempus AI and Pathos AI have entered a multi-year, strategic collaboration to build a multimodal foundation model in oncology.  The model will be used to gather biological and clinical insights, discover novel drug targets, and develop therapeutics for the broader oncology community.  Upon completion,… Read More

#Business & Investment #Cancer Research #News

Tumour microenvironment
#Collaboration #Genetics / genomics #Oncology #Solid tumours

AACR data shows promise for patients with solid tumour types

Data from the Friends of Cancer Research’s (Friends’) ctMoniTR Project, recently published in Clinical Cancer Research (CCR), demonstrate a strong association between changes in levels of circulating tumour DNA (ctDNA) and treatment outcomes. This offers the potential for integration of ctDNA analysis in therapeutic development programmes, and clinical cancer… Read More

#Cancer Research #News

CAR-T therapy
#CAR-T #Cell therapy #Haematology #Lymphoma #March Biosciences #Phase II trial

Phase II trial starts for CAR-T therapy in T-cell lymphoma

March Biosciences (March Bio) announced that the first patient has been dosed in its Phase II clinical trial evaluating MB-105, a first-in-class CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.   “This represents a significant milestone in advancing MB-105 as a potential treatment… Read More

#Cancer Research #News

Melanoma
#Aulos Bioscience #Melanoma #Monoclonal antibodies #Oncology #Phase II trial

Aulos doses first patient in Phase II cohort for melanoma treatment

Aulos Bioscience has dosed its first patient with a combination of AU-007, the anti-PD-1 antibody nivolumab and low-dose, subcutaneous aldesleukin in a Phase II expansion cohort focused on second-line treatment of melanoma.   The new cohort forms part of the company’s Phase I/II clinical trial of AU-007… Read More

#Cancer Research #News

Non-small cell lung cancer
#Candel Therapeutics #Immunotherapy #Lung cancer #Oncology #Phase II trial

Unique immunotherapy extends survival in advanced NSCLC

Candel Therapeutics’ CAN-2409 has demonstrated a median overall survival (mOS) of 24.5 months in a Phase IIa clinical trial in patients with stage III/IV non-small cell lung cancer (NSCLC).  The 46 evaluable patients, who are nonresponsive to immune checkpoint inhibitor (ICI) treatment, received two courses of CAN-2409. Read More

#Cancer Research #Editor's Choice #News

#Cancer Research Manchester Institute #Cell Science #Lung cancer #Non-animal model (NAM) #Oncology

Cell-based lung cancer model could unlock targeted treatments

Scientists at the Cancer Research Manchester Institute have created a new model of Lung Squamous Cell Carcinoma (LUSC) to study the development, activity, and vulnerabilities of the disease.   In the UK, around 80 to 85% of lung cancers are non-small cell lung cancer, of which squamous cell… Read More

#Cancer Research #News

Trophy
#AACR #Award #Events #Janssen #Oncology

Janssen’s Hait honoured for achievements in cancer research

The 2025 AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research will be presented to William Hait, Fellow of the AACR Academy, during the AACR Annual Meeting 2025.  Hait served as the Global Head of Janssen Research and Development and was the executive vice president,… Read More

#Cancer Research #News